Aardvark Therapeutics, Inc Common Stock

Yahoo Finance • 22 days ago

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price grew 91.62% from a year ago, while it registered an 80.98% increase year-to-date. On April 16, Vir Biotechnolog... Full story

Yahoo Finance • 30 days ago

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimin... Full story

Yahoo Finance • 2 months ago

Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is one of the penny stocks with potential to rise 1000 percent. Aardvark Therapeutics said on March 23, 2026, that it had voluntarily paused its Phase 3 HERO and open-label extension trials of ARD... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton... Full story

Yahoo Finance • 2 months ago

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aardvark Therapeutics, Inc., ("Aardvark" or the "Company") (NASDAQ:AARD) investors that the firm has initiated an investigation into possible securities fraud,... Full story

Yahoo Finance • 2 months ago

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathwa... Full story

Yahoo Finance • 3 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathwa... Full story

Yahoo Finance • 5 months ago

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy fr... Full story

Yahoo Finance • 5 months ago

Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today! Carvana What happened? On Mond... Full story

Yahoo Finance • 6 months ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) N... Full story

Yahoo Finance • 6 months ago

Datadog, Trade Desk upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: KeyBanc upgraded Datadog (DDOG) to Overw... Full story

Yahoo Finance • 8 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathw... Full story

Yahoo Finance • 9 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathwa... Full story

Yahoo Finance • 9 months ago

Aardvark Therapeutics GAAP EPS of -$0.66

* Aardvark Therapeutics press release [https://seekingalpha.com/pr/20200202-aardvark-therapeutics-reports-second-quarter-2025-financial-results-and-provides-pipeline-and] (NASDAQ:AARD [https://seekingalpha.com/symbol/AARD]): Q2 GAAP EPS... Full story

Yahoo Finance • 9 months ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 ST... Full story

Yahoo Finance • 9 months ago

Aardvark reports weight loss benefits of ARD-201 in preclinical study

SAN DIEGO - Aardvark Therapeutics, Inc. (NASDAQ:AARD), a $242 million market cap biotech company with a strong financial health score according to InvestingPro, announced Tuesday that its investigational drug ARD-201 demonstrated approxima... Full story

Yahoo Finance • 10 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseas... Full story

Yahoo Finance • 10 months ago

H.C. Wainwright initiates coverage on Aardvark Therapeutics stock with Buy rating

Investing.com - H.C. Wainwright initiated coverage on Aardvark Therapeutics Inc (NASDAQ:AARD) Monday with a Buy rating and a $40.00 price target. According to InvestingPro data, analyst targets for AARD range from $20 to $50, with the st... Full story

Yahoo Finance • 11 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathwa... Full story

Yahoo Finance • 12 months ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SA... Full story